C

CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765

Watchlist Manager
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Watchlist
Price: 42 CNY -2.67%
Market Cap: 112.2B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CSPC Innovation Pharmaceutical Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 42 CNY, CSPC Innovation Pharmaceutical Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CSPC Innovation Pharmaceutical Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

56.7
P/S
P/S
Price to Sales
56.7
vs History
0
vs Industry
5
Median 3Y
14.4
Median 5Y
13
Industry
2.3
Forward
24.4
More Details
2 089.2
P/E
P/E
Price to Earnings
2 089.2
vs History
0
vs Industry
1
Median 3Y
63.7
Median 5Y
57.7
Industry
19.8
Forward
149.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
4
Median 3Y
37.2
Median 5Y
49.7
Industry
14.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
6
Median 3Y
43.6
Median 5Y
74.4
Industry
22.2
More Details
29.4
P/B
P/B
Price to Book Value
29.4
vs History
0
vs Industry
2
Median 3Y
8.8
Median 5Y
6.5
Industry
1.9
More Details
56.1
EV/S
EV/S
Enterprise Value to Sales
56.1
vs History
0
vs Industry
5
Median 3Y
13
Median 5Y
11.8
Industry
2.4
Forward
24.2
More Details
134
EV/GP
EV/GP
Enterprise Value to Gross Profit
134
vs History
0
vs Industry
2
Median 3Y
29.2
Median 5Y
24.3
Industry
4.7
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
0
Median 3Y
35.3
Median 5Y
44.6
Industry
12
Forward
129.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
1
Median 3Y
35.3
Median 5Y
44.6
Industry
14.9
Forward
126.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
4
Median 3Y
33.5
Median 5Y
45.7
Industry
13.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
5
Median 3Y
40.5
Median 5Y
67.2
Industry
17.2
More Details
27.1
EV/IC
EV/IC
Enterprise Value to IC
27.1
vs History
0
vs Industry
5
Median 3Y
11.1
Median 5Y
11
Industry
1.7
More Details

Multiples Across Competitors

Competitors Multiples
CSPC Innovation Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
112.2B CNY 56.7 2 089.2 -425 -425
US
Eli Lilly and Co
NYSE:LLY
696.3B USD 15.5 65.8 38.4 42.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
370.4B USD 4.2 26.3 12.3 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.5 12.2 13.9
CH
Roche Holding AG
SIX:ROG
202.8B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.1B CHF 4.3 18.8 11.4 14.6
UK
AstraZeneca PLC
LSE:AZN
159B GBP 3.9 29.9 126 192.4
US
Merck & Co Inc
NYSE:MRK
193.6B USD 3 11.3 7.7 9.1
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
FR
Sanofi SA
PAR:SAN
112.8B EUR 2.5 19.6 8.6 12.6
P/E Multiple
Earnings Growth PEG
CN
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Average P/E: 255.2
2 089.2
214%
9.8
US
Eli Lilly and Co
NYSE:LLY
65.8
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.3
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.5
19%
1
CH
Roche Holding AG
SIX:ROG
17.6
16%
1.1
CH
Novartis AG
SIX:NOVN
18.8
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
29.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.3
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
19.6
28%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Average EV/EBITDA: 433.2
Negative Multiple: -425 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.4
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.2
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.9
7%
1.4
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126
9%
14
US
Merck & Co Inc
NYSE:MRK
7.7
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
FR
Sanofi SA
PAR:SAN
8.6
6%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Average EV/EBIT: 1 866.6
Negative Multiple: -425 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.3
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.8
9%
1.3
CH
Novartis AG
SIX:NOVN
14.6
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.4
21%
9.2
US
Merck & Co Inc
NYSE:MRK
9.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
FR
Sanofi SA
PAR:SAN
12.6
14%
0.9

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 247,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.